Study Summary
It is a single-arm, open-label clinical study to assess the safety and efficacy of the Anti-CD19 Universal CAR-T Cells injection for patients with CD19+ refractory/relapsed B cell acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma.
Want to learn more about this trial?
Request More InfoInterventions
Anti-CD19 Universal CAR-T Cells injectionBIOLOGICAL
Anti-CD19 Universal CAR-T Cells injection will be administered by vein after lymphodepletion.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Kunming | Yunnan | China |